Joyce Veld1, Elizabeth K O'Donnell2, Michaela R Reagan3, Andrew J Yee2, Martin Torriani1, Clifford J Rosen3, Miriam A Bredella4. 1. Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Yawkey 6E, 55 Fruit Street, Boston, MA, 02114, USA. 2. Division of Hematology-Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA. 3. Maine Medical Center Research Institute, Scarborough, ME, 04074, USA. 4. Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Yawkey 6E, 55 Fruit Street, Boston, MA, 02114, USA. mbredella@mgh.harvard.edu.
Abstract
OBJECTIVE: To determine abdominal adipose tissue parameters on PET/CT in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) that may serve as predictors of progression of MGUS to MM. We hypothesized that patients with MM had higher abdominal adiposity and higher fat metabolic activity compared to patients with MGUS. MATERIALS AND METHODS: Our retrospective study was IRB approved and HIPAA compliant. The study group comprised 40 patients (mean age 64 ± 13 years) with MGUS and 32 patients (mean age 62 ± 10 years) with recently diagnosed MM (mean time since diagnosis of MM 3.0 ± 3.9 months) who had not undergone MM treatment. All patients underwent whole body FDG-PET/CT. Total abdominal adipose tissue (TAT), abdominal subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) cross sectional areas (CSA) (cm(2)) and metabolic activity (SUV) were assessed. Groups were compared using ANOVA. ROC curve analysis was performed to determine cutoff values for abdominal adipose tissue parameters to detect MM. RESULTS: Patients with recently diagnosed MM had higher TAT and SAT CSA (p ≤ 0.03) and higher fat metabolic activity (p < 0.01). VAT metabolic activity showed the highest sensitivity and specificity for identifying patients with MM (area under the curve 0.95 with cutoff value of >0.34, sensitivity 90.6 %, specificity 92.5 %, p < 0.0001). CONCLUSIONS: Patients who were recently diagnosed with MM had higher abdominal fat CSA and higher fat metabolic activity compared to patients with MGUS. These parameters may serve as novel biomarkers of progression of MGUS to MM.
OBJECTIVE: To determine abdominal adipose tissue parameters on PET/CT in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) that may serve as predictors of progression of MGUS to MM. We hypothesized that patients with MM had higher abdominal adiposity and higher fat metabolic activity compared to patients with MGUS. MATERIALS AND METHODS: Our retrospective study was IRB approved and HIPAA compliant. The study group comprised 40 patients (mean age 64 ± 13 years) with MGUS and 32 patients (mean age 62 ± 10 years) with recently diagnosed MM (mean time since diagnosis of MM 3.0 ± 3.9 months) who had not undergone MM treatment. All patients underwent whole body FDG-PET/CT. Total abdominal adipose tissue (TAT), abdominal subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) cross sectional areas (CSA) (cm(2)) and metabolic activity (SUV) were assessed. Groups were compared using ANOVA. ROC curve analysis was performed to determine cutoff values for abdominal adipose tissue parameters to detect MM. RESULTS:Patients with recently diagnosed MM had higher TAT and SAT CSA (p ≤ 0.03) and higher fat metabolic activity (p < 0.01). VAT metabolic activity showed the highest sensitivity and specificity for identifying patients with MM (area under the curve 0.95 with cutoff value of >0.34, sensitivity 90.6 %, specificity 92.5 %, p < 0.0001). CONCLUSIONS:Patients who were recently diagnosed with MM had higher abdominal fat CSA and higher fat metabolic activity compared to patients with MGUS. These parameters may serve as novel biomarkers of progression of MGUS to MM.
Authors: Casey R Doucette; Mark C Horowitz; Ryan Berry; Ormond A MacDougald; Rea Anunciado-Koza; Robert A Koza; Clifford J Rosen Journal: J Cell Physiol Date: 2015-09 Impact factor: 6.384
Authors: Dominik D Alexander; Pamela J Mink; Hans-Olov Adami; Philip Cole; Jack S Mandel; Martin M Oken; Dimitrios Trichopoulos Journal: Int J Cancer Date: 2007 Impact factor: 7.396
Authors: Thomas Christen; Yuri Sheikine; Viviane Z Rocha; Shelley Hurwitz; Allison B Goldfine; Marcelo Di Carli; Peter Libby Journal: JACC Cardiovasc Imaging Date: 2010-08
Authors: Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar Journal: Blood Date: 2009-01-29 Impact factor: 22.113
Authors: Anna M Wolf; Dominik Wolf; Holger Rumpold; Barbara Enrich; Herbert Tilg Journal: Biochem Biophys Res Commun Date: 2004-10-15 Impact factor: 3.575
Authors: Stefanie A de Boer; Daan S Spoor; Riemer H J A Slart; Douwe J Mulder; Melanie Reijrink; Ronald J H Borra; Gerbrand M Kramer; Otto S Hoekstra; Ronald Boellaard; Marcel J Greuter Journal: Mol Imaging Biol Date: 2019-02 Impact factor: 3.488
Authors: Geffen Kleinstern; Dirk R Larson; Cristine Allmer; Aaron D Norman; Grace Muntifering; Jason Sinnwell; Alissa Visram; Vincent Rajkumar; Angela Dispenzieri; Robert A Kyle; Susan L Slager; Shaji Kumar; Celine M Vachon Journal: Blood Cancer J Date: 2022-04-19 Impact factor: 9.812